amikacin therapy exacerbation pseudomonas aeruginosa infection patient cystic fibrosis amikacin new semisynthetic aminoglycoside antibiotic activity pseudomonas aeruginosa used treat 22 acute exacerbation chronic pulmonary infection 18 patient cystic fibrosis patient ranged 5 32 year age mucoid p aeruginosa isolated sputum amikacin dose usually 75 mgkg every eight hour increased 10 mgkg andor carbenicillin added selected case depending clinical course although p aeruginosa eliminated patient sputum except two case good clinical response 19 22 course significant improvement chest xray film spirometry arterial oxygen tension documented 11 17 course one instance serum creatinine level elevation could attributed antibiotic two patient showed minimal 15 db unilateral highfrequency hearing loss serial audiogram activity many gentamicinresistant strain high blood level among attractive property amikacin amikacin clinically effective treating pseudomonasassociated pulmonary infection complicating cystic fibrosis